---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000065"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:53:28.806002+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M

## Summary
- Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.
- Optimized profile cohort (N=35): 86% ORR, 63% CR rate, 53% 12-month PFS; median follow-up 11.8 months.
- CB-011 (BCMA) dose escalation: 92% ORR, 75% CR/sCR at RDE (450M cells) in BCMA-naïve r/r MM; dose expansion by end 2025.
- Planned pivotal phase 3 for vispa-cel in 2L LBCL: FDA recommends randomized controlled trial, ~250 patients, PFS primary endpoint.
- Preliminary cash, equivalents, and marketable securities as of Sep 30, 2025: approximately $159.2 million.

## SEC filing metadata
- accession: 0001619856-25-000065
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/0001619856-25-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/crbu-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000065
- JSON: https://secwatch.observer/filing/0001619856-25-000065.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.